Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with streptococcus pneumoniae in mice ∇

Infection and Immunity

Volumn 77, Issue 4, 2009, Pages 1502-1513

  Tian, Haijun ^a   Weber, Sarah ^a   Thorkildson, Peter ^b   Kozel, Thomas R ^b   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1E2 MONOCLONAL ANTIBODY; 5F6 MONOCLONAL ANTIBODY; 7A9 MONOCLONAL ANTIBODY; FC RECEPTOR IIB; MONOCLONAL ANTIBODY; PNEUMOCOCCUS POLYSACCHARIDE; RB6 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; OPSONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL KILLING; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG EFFICACY; FEMALE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; ANIMAL; ANTIBODY SPECIFICITY; BACTERIAL MEMBRANE; C57BL MOUSE; CLASSIFICATION; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; MORTALITY; PATHOGENICITY; SEROTYPING; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BACTERIAL CAPSULES; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 63149175859     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01075-08     Document Type: Article

References (90)

1. Albrich, W. C., W. Baughman, B. Schmotzer, and M. M. Farley. 2007. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin. Infect. Dis. 44:1569-1576.
2. Ali, F., M. E. Lee, F. Iannelli, G. Pozzi, T. J. Mitchell, R. C. Read, and D. H. Dockrell. 2003. Streptococcus pneumoniae-associated human macrophage apoptosis after bacterial internalization via complement and Fcy receptors correlates with intracellular bacterial load. J. Infect. Dis. 188:1119-1131.
3. Anttila, M., M. Voutilainen, V. Jantti, J. Eskola, and H. Kayhty. 1999. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118:402-407.
4. Arulanandam, B. P., J. M. Lynch, D. E. Briles, S. Hollingshead, and D. W. Metzger. 2001. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69:6718-6724.
5. Baxendale, H. E., and D. Goldblatt. 2006. Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies. Infect. Immun. 74:1025-1031.
6. Bender, J. M., K. Ampofo, K. Korgenski, J. Daly, A. T. Pavia, E. O. Mason, and C. L. Byington. 2008. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin. Infect. Dis. 46:1346-1352.
7. Bogaert, D., M. Sluijter, R. de Groot, and P. W. Hermans. 2004. Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine. Vaccine 22:4014-4020.
8. Briles, D. E., C. Forman, J. C. Horowitz, J. E. Volanakis, W. H. Benjamin, Jr., L. S. McDaniel, J. Eldridge, and J. Brooks. 1989. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect. Immun. 57:1457-1464.
9. Brownlie, R. J., K. E. Lawlor, H. A. Niederer, A. J. Cutler, Z. Xiang, M. R. Clatworthy, R. A. Floto, D. R. Greaves, P. A. Lyons, and K. G. Smith. 2008. Distinct cell-specific control of autoimmunity and infection by FcyRIIb. J. Exp. Med. 205:883-895.
10. Bruyn, G. A., B. J. Zegers, and R. van Furth. 1992. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin. Infect. Dis. 14:251-262.
11. Buchwald, U. K., A. Lees, M. Steinitz, and L. Pirofski. 2005. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect. Immun. 73:333.
12. Buissa-Filho, R., R. Puccia, A. F. Marques, F. A. Pinto, J. E. Munoz, J. D Nosanchuk, L. R. Travassos, and C. P. Taborda. 2008. The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratra- cheally with the fungus. Infect. Immun. 76:3321-3328.
13. Burns, T., M. Abadi, and L. Pirofski. 2005. Modulation of the lung inflammatory response to serotype 8 pneumococcus infection by a human monoclonal immunoglobulin M to serotype 8 capsular polysaccharide. Infect. Immun. 73:4530-4538.
14. Burns, T., Z. Zhong, M. Steinitz, and L. A. Pirofski. 2003. Modulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharide. Infect. Immun. 71:6775-6783.
15. Butler, J. C., R. F. Breiman, J. F. Campbell, H. B. Lipman, C. V. Broome, and R. R. Facklam. 1993. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270:1826-1831.
16. Byington, C. L., K. Korgenski, J. Daly, K. Ampofo, A. Pavia, and E. O. Mason. 2006. Impact of the pneumococcal conjugate vaccine on pneumo- coccal parapneumonic empyema. Pediatr. Infect. Dis. J. 25:250-254.
17. Casadevall, A., and M. D. Scharff. 1994. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimi-crob. Agents Chemother. 38:1695-1702.
18. Centers for Disease Control and Prevention. 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States,1998-2003. MMWR Morb. Mortal. Wkly. Rep. 54:893-897.
19. Chang, Q., Z. Zhong, A. Lees, M. Pekna, and L. Pirofski. 2002. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin loci. Infect. Immun. 70:4977-4986.
20. Clatworthy, M. R., and K. G. Smith. 2004. FcγRIIb balances efficient patho-gen clearance and the cytokine-mediated consequences of sepsis. J. Exp. Med. 199:717-723.
21. Clatworthy, M. R., L. Willcocks, B. Urban, J. Langhorne, T. N. Williams, N. Peshu, N. A. Watkins, R. A. Floto, and K. G. Smith. 2007. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcγRIIb reduce susceptibility to malaria. Proc. Natl. Acad. Sci. USA 104:7169-7174.
22. Committee on New Directions in the Study of Antimicrobial Therapeutics: Immunomodulation. 2006. Treating infectious diseases in a microbial world: report of two workshops on novel antimicrobial therapies, p. 13-20. National Academies Press, Washington, DC.
23. Dockrell, D. H., M. Lee, D. H. Lynch, and R. C. Read. 2001. Immune- mediated phagocytosis and killing of Streptococcus pneumoniae are associated with direct and bystander macrophage apoptosis. J. Infect. Dis. 184:713-722.
24. Duro, R. M., D. Netski, P. Thorkildson, and T. R. Kozel. 2003. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan. Clin. Diagn. Lab. Immunol. 10:252-258.
25. Fabrizio, K., A. Groner, M. Boes, and L. A. Pirofski. 2007. A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin. Vaccine Immunol. 14:382-390.
26. Felton, L. D. 1928. The units of protective antibody in anti-pneumococcus serum and antibody solution. J. Infect. Dis. 43:531.
27. Fine, D. P., J. L. Kirk, G. Schiffman, J. E. Schwinle, and J. C. Guckinan. 1988. Analysis of humoral and phagocytic defenses against Streptococcus pneumoniae serotypes 1 and 3. J. Lab. Clin. Med. 112:487-497.
28. Glover, D. T., S. K. Hollingshead, and D. E. Briles. 2008. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect. Immun. 76:2767-2776.
29. Goodner, K., and F. L. Horsfall. 1935. The protective action of type I antipneumococcus serum in mice. I. Quantitative aspects of the mouse protection test. J. Exp. Med. 62:359-374.
30. Grijalva, C. G., J. P. Nuorti, P. G. Arbogast, S. W. Martin, K. M. Edwards, and M. R. Griffin. 2007. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369:1179-1186.
31. Hicks, L. A., L. H. Harrison, B. Flannery, J. L. Hadler, W. Schaffner, A. S.Craig, D. Jackson, A. Thomas, B. Beall, R. Lynfield, A. Reingold, M. M. Farley, and C. G. Whitney. 2007. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196:1346-1354.
32. Hostetter, M. K. 1999. Opsonic and nonopsonic interactions of C3 with Streptococcus pneumoniae. Microb. Drug Resist. 5:85-89.
33. Hu, B. T., X. Yu, T. R. Jones, C. Kirch, S. Harris, S. W. Hildreth, D. V. Madore, and S. A. Quataert. 2005. Approach to validating an opsonophago- cytic assay for Streptococcus pneumoniae. Clin. Diagn. Lab. Immunol. 12:287-295.
34. Jackson, L. A., K. M. Neuzil, O. Yu, P. Benson, W. E. Barlow, A. L. Adams, C. A. Hanson, L. D. Mahoney, D. K. Shay, W. W. Thompson, and the Vaccine Study Datalink. 2003. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 348:1755.
35. Jansen, W. T. M., J. Gootjes, M. Zelle, D. Madore, J. Verhoef, H. Snippe, and F. M. Verheul. 1998. Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin. Diagn. Lab. Immunol. 5:703-710.
36. Johnson, S. E., L. Rubin, S. Romero-Steiner, J. K. Dykes, L. B. Pais, A. Rizvi, E. Ades, and G. M. Carlone. 1999. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J. Infect. Dis. 180:133-140.
37. Kadioglu, A., and P. W. Andrew. 2004. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol. 25:143-149.
38. Knapp, S., J. C. Leemans, S. Florquin, J. Branger, N. A. Maris, J. Pater, N. van Rooijen, and P. T. van der Poll. 2003. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am. J. Respir. Crit. Care Med. 167:171-179.
39. Knapp, S., C. W. Wieland, C. van't Veer, O. Takeuchi, S. Akira, S. Florquin, and P. T. van der Poll. 2004. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J. Immunol. 172:3132-3138.
40. Kozel, T. R., P. Thorkildson, S. Brandt, W. H. Welch, J. A. Lovchik, D. P. AuCoin, J. Vilai, and C. R. Lyons. 2007. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect. Immun. 75:152-163.
41. Krishnamurthy, V. M., L. J. Quinton, L. A. Estroff, S. J. Metallo, J. M. Isaacs, J. P. Mizgerd, and G. M. Whitesides. 2006. Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunc- tional polyacrylamide. Biomaterials 27:3663-3674.
42. Kumar, D., A. Humar, A. Plevneshi, K. Green, G. V. Prasad, D. Siegal, and A. McGeer. 2007. Invasive pneumococcal disease in solid organ transplant recipients-10-year prospective population surveillance. Am. J. Transplant. 7:1209-1214.
43. Lexau, C. A., R. Lynfield, R. Danila, T. Pilishvili, R. Facklam, M. M. Farley, L. H. Harrison, W. Schaffner, A. Reingold, N. M. Bennett, J. Hadler, P. R. Cieslak, and C. G. Whitney. 2005. Changing epidemiology of invasive pneu- mococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043-2051.
44. Li, J., A. J. Szalai, S. K. Hollingshead, M. H. Nahm, and D. E. Briles. 2009. Antibody to the type 3 capsule facilitates immune adherence of pneumococci to erythrocytes and augments their transfer to macrophages. Infect. Immun. 77:464-471.
45. Madhi, S. A., P. Adrian, L. Kuwanda, C. Cutland, W. C. Albrich, and K. P. Klugman. 2007. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae-and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization-in HIV-Infected and HIV-uninfected children. J. Infect. Dis. 196:1662-1666.
46. Maglione, P. J., J. Xu, A. Casadevall, and J. Chan. 2008. Fc7 receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J. Immunol. 180:3329-3338.
47. Marks, M., T. Burns, M. Abadi, B. Seyoum, J. Thornton, E. Tuomanen, and L. A. Pirofski. 2007. Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice. Infect. Immun. 75:1586-1597.
48. Martens, P., S. W. Worm, B. Lundgren, H. B. Konradsen, and T. Benfield. 2004. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect. Dis. 4:21.
49. McNeely, T., S. Luo, W. Manger, W. Herber, T. Schofield, C. Tan, K Newman, J. Sadoff, J. Donnelly, and A. Cross. 2006. Development of an opsonin inhibition assay for evaluation of complex polysaccharide protective epitopes. Vaccine 24:1941-1948.
50. Mednick, A. J., M. Feldmesser, J. Rivera, and A. Casadevall. 2003. Neutro- penia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur. J. Immunol. 33:1744-1753.
51. Melegaro, A., and W. J. Edmunds. 2004. The 23-valent pneumococcal poly- saccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur. J. Epidemiol. 19:353-363.
52. Mukherjee, J., T. R. Kozel, and A. Casadevall. 1998. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. J. Immunol. 161:3557-3567.
53. Mykietiuk, A., J. Carratala, A. Dominguez, A. Manzur, N. Fernandez-Sabe, J. Dorca, F. Tubau, F. Manresa, and F. Gudiol. 2006. Effect of prior pneu- mococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 25:457-462.
54. Nahm, M. H., J. V. Olander, and M. Magyarlaki. 1997. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J. Infect. Dis. 176:698-703.
55. Neuberger, M. S., and K. Rajewsky. 1981. Activation of mouse complement by monoclonal mouse antibodies. Eur. J. Immunol. 11:1012-1016.
56. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcγ receptors: old friends and new family members. Immunity 24:19-28.
57. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47.
58. Oosterhuis-Kafeja, F., P. Beutels, and P. Van Damme. 2007. Immunogenic- ity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25:2194-2212.
59. Ortqvist, A., J. Hedlund, and M. Kalin. 2005. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin. Respir. Crit. Care Med. 26:563-574.
60. Park-Min, K. H., N. V. Serbina, W. Yang, X. Ma, G. Krystal, B. G. Neel, S. L. Nutt, X. Hu, and L. B. Ivashkiv. 2007. FcγRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26:67-78.
61. Pekna, M., M. A. Hietala, A. Landin, A. K. Nilsson, C. Lagerberg, C. Bet- sholtz, and M. Pekny. 1998. Mice deficient for the complement factor B develop and reproduce normally. Scand. J. Immunol. 47:375-380.
62. Prymula, R., P. Peeters, V. Chrobok, P. Kriz, E. Novakova, E. Kaliskova, I. Kohl, P. Lommel, J. Poolman, J. P. Prieels, and L. Schuerman. 2006. Pneu- mococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367:740-748.
63. Reed, W. P., D. L. Stromquist, and R. C. Williams, Jr. 1983. Agglutination and phagocytosis of pneumococci by immunoglobulin G antibodies of restricted heterogeneity. J. Lab Clin. Med. 101:847-856.
64. Ren, B., A. J. Szalai, S. K. Hollingshead, and D. E. Briles. 2004. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72:114-122.
65. Retter, I., H. H. Althaus, R. Munch, and W. Muller. 2005. VBASE2, an integrative V gene database. Nucleic Acids Res. 33:D671-D674.
66. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
67. Romero-Steiner, S., C. E. Frasch, G. Carlone, R. A. Fleck, D. Goldblatt, and M. H. Nahm. 2006. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin. Vaccine Immunol. 13:165-169.
68. Romero-Steiner, S., D. Libutti, L. B. Pais, et al. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Di- agn. Lab. Immunol. 4:415-422.
69. Russell, N., J. R. Corvalan, M. L. Gallo, C. G. Davis, and L. Pirofski. 2000. Production of protective human anti-pneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect. Immun. 68:1820-1826.
70. Saeland, E., J. H. Leusen, G. Vidarsson, W. Kuis, E. A. Sanders, I. Jonsdot- tir, and J. G. Van de Winkel. 2003. Role of leukocyte immunoglobuin G receptors in vaccine-induced immunity to Streptococcus pneumoniae. J. Infect. Dis. 187:1686-1693.
71. Saeland, E., G. Vidarsson, and I. Jonsdottir. 2000. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb. Pathog. 29:81-91.
72. Saeland, E., G. Vidarsson, J. H. Leusen, E. Van Garderen, M. H. Nahm, H. Vile-Weekhout, V. Walraven, A. M. Stemerding, J. S. Verbeek, G. T. Rijkers, W. Kuis, E. A. Sanders, and J. G. Van de Winkel. 2003. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumo- coccal antibodies in mice. J. Immunol. 170:6158-6164.
73. Schlesinger, M., U. Mashal, J. Levy, and Z. Fishelson. 1993. Hereditary properdin deficiency in three families of Tunisian Jews. Acta Paediatr. 82:744-747.
74. Schuerman, L., R. Prymula, V. Chrobok, I. Dieussaert, and J. Poolman. 2007. Kinetics of the immune response following pneumococcal PD conjugate vaccination. Vaccine 25:1953-1961.
75. Scott, D. A., S. F. Komjathy, B. T. Hu, S. Baker, L. A. Supan, C. A. Monahan, W. Gruber, G. R. Siber, and S. P. Lockhart. 2007. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25:6164-6166.
76. Shapiro, E. D., A. T. Berg, R. Austrian, D. Schroeder, V. Parcells, A. Mar- golis, R. K. Adair, and J. D. Clemens. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1425-1460.
77. Spellberg, B., J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards, Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38:1279-1286.
78. Stephens-Romero, S. D., A. J. Mednick, and M. Feldmesser. 2005. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect. Immun. 73:114-125.
79. Sun, K., S. L. Salmon, S. A. Lotz, and D. W. Metzger. 2007. Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect. Immun. 75:1196-1202.
80. Sylvestre, D., R. Clynes, M. Ma, H. Warren, M. C. Carroll, and J. V. Ravetch. 1996. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 184:2385-2392.
81. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J. V. Ravetch. 1994. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76:519-529.
82. Takai, T., M. Ono, M. Hikida, H. Ohmori, and J. V. Ravetch. 1996. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379:346-349.
83. Test, S. T., J. K. Mitsuyoshi, and Y. Hu. 2005. Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell- dependent protein carrier. Infect. Immun. 73:277-286.
84. Thornton, J., and L. S. McDaniel. 2005. THP-1 monocytes up-regulate intercellular adhesion molecule 1 in response to pneumolysin from Streptococcus pneumoniae. Infect. Immun. 73:6493-6498.
85. Tian, H., A. Groner, M. Boes, and L. A. Pirofski. 2007. Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice. Infect. Immun. 75:1643-1650.
86. UNICEF/WHO. 2006. Pneumonia: the forgotten killer of children, p. 34-37. WHO Press, New York, NY.
87. Vila-Corcoles, A., O. Ochoa-Gondar, C. Llor, I. Hospital, T. Rodriguez, and A. Gomez. 2005. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. Eur. Respir. J. 26:1086-1091.
88. Wessels, M. R., R. Butko, N. Ma, H. B. Warren, A. L. Lage, and M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92:11490-11494.
89. Zhong, Z., T. Burns, Q. Chang, M. Carroll, and L. Pirofski. 1999. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect. Immun. 67:4119-4127.
90. Zhong, Z., and L. Pirofski. 1996. Opsonization of Cryptococcus neoformans by human anti-glucuronoxylomannan antibodies. Infect. Immun. 64:3446-3450.